Kenna Nagy
YOU?
Author Swipe
View article: Repositioning the Early Pathology of Type 1 Diabetes to the Extraislet Vasculature
Repositioning the Early Pathology of Type 1 Diabetes to the Extraislet Vasculature Open
Type 1 diabetes (T1D) is a prototypic T cell–mediated autoimmune disease. Because the islets of Langerhans are insulated from blood vessels by a double basement membrane and lack detectable lymphatic drainage, interactions between endocrin…
View article: Therapeutic anti-glycan antibodies against antibiotic resistant <i>Staphylococcus aureus</i>
Therapeutic anti-glycan antibodies against antibiotic resistant <i>Staphylococcus aureus</i> Open
Antibiotic resistance threatens clinical control of bacterial infections while the genetic adaptability of microbes continues to outpace small-molecule development. The combinatorial diversity of antibodies offers a solution to this proble…
View article: An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
An alternate conformation of HCV E2 neutralizing face as an additional vaccine target Open
An alternate conformation is found for the major antibody target on hepatitis C virus to aid in rational vaccine design.
View article: Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines
Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines Open
An HCV vaccine strategy displays optimized E2 cores on nanoparticles for eliciting a cross-neutralizing B cell response.
View article: Rational design of hepatitis C virus E2 core nanoparticle vaccines
Rational design of hepatitis C virus E2 core nanoparticle vaccines Open
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical for cell entry with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell-based HCV vaccine development throu…
View article: Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors
Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors Open
Significance Hepatitis C virus (HCV) infects 1–2% of the world’s population, but a vaccine to limit spreading of this silent killer is unavailable. A leading strategy in vaccine design to counter the genetic variability of HCV is to elicit…